Alzheimer's disease (AD) is a complex disorder for which various in vivo models exist. The TgCRND8 mouse, transgenic for the human amyloid precursor protein, is an aggressive early onset model of brain amyloid deposition. Preliminary studies revealed that when the transgene is expressed on an A/J genetic background, these mice not only survive longer but also deposit less parenchymal amyloid-b (Ab) peptides as compared to those on a C57BL/6 background. We performed a genome-wide study of an F2 intercross between TgCRND8 on an A/J background and C57BL/6 mice, to identify genetic modulators of amyloid accumulation and deposition. We identified four highly significant QTLs that together account for 55% of the phenotypic variance in the number of plaques (Thioflavin S). QTLs were found on the distal part of chromosome 4 with an LOD score of 8.1 at D4Mit251, on chromosome 11 with an LOD score of 5.5 at D11Mit242, on chromosome 9 with an LOD score of 5.0 at D9Mit336 and on the proximal part of chromosome 8 with an LOD score of 4.5 at D8Mit223. A/J alleles at these loci are protective and all decreased the amount of Ab deposition. Interestingly, the QTL on chromosome 11 is also significantly linked to the levels of brain Ab 42 and Ab 40 . Although these QTLs do not control the levels of plasmatic Ab, other regions on chromosomes 1 and 6 show significant linkage. Further characterization of these QTL regions may lead to the identification of genes involved in the pathogenesis of AD.
INTRODUCTION
Alzheimer's disease (AD), the leading cause of senile dementia, is characterized by a gradual decline of cognitive functions together with the appearance of amyloid deposits, neurofibrillary tangles, and neuronal cell loss in the brain. Amyloid-b (Ab) is a key culprit in the pathogenesis of AD (1) . Although it has been well accepted that an increased concentration of Ab peptides results in the formation of cerebral amyloid plaques, mounting evidence indicates that Ab accumulation occurs prior to and may be the root cause of the other histopathological abnormalities associated with AD (2) . In addition, soluble metastable oligomeric forms of Ab distinct from protofibrils and fibrils have also been implicated in early synaptic damage that ultimately results in neuronal loss (3) .
Although the majority of AD cases are sporadic, genetic studies in families with early-onset AD have revealed disease-causing mutations in three proteins: amyloid precursor protein (APP) on chromosome 21, Presenilin 1 and 2, respectively, on chromosome 14 and 1 (4 -7). Mutations found within these genes all favor the processing of the APP protein resulting in an increased production of Ab. In addition, linkage studies revealed the presence of an AD susceptibility locus on chromosome 19 in late onset AD patients (8) . The 14 allele of apolipoprotein E was shown to account for this linkage and carriers present a 4-fold increased risk of developing AD (9 -11) . Collectively, these four genes account for less than 50% of the genetic variance seen in AD (12) . Over the past 10 years, there has been a concerted effort to identify additional genes involved in the development of this disease either by performing genome-wide linkage studies or by performing candidate gene-specific association studies using cohorts of AD patients and their relatives (reviewed in 13). Although many loci have been examined, functional gene # The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org polymorphisms affecting the onset or progression of AD have not been identified yet (14) , but it is anticipated that additional genes that remain to be identified will not account for such large effects.
Much of our understanding of the molecular mechanisms at work in the Alzheimer's brain has come from studying transgenic mouse models developed to mimic the human disease. Each model recapitulates some of the neuropathological changes and cognitive deficits characteristic of AD. Interestingly, a few groups have described that similar to AD in humans, the genetic variability found among the different inbred mouse strains can account for differences observed in various models overexpressing variants of human APP. Carlson et al. (15) specifically demonstrated that in FVB or C57BL/6 (B6) genetic backgrounds, APP overexpression is lethal at an early age, whereas the same level of APP overexpression in outbred mice results only in amyloid plaque accumulation. More recently, using a genome-wide study in Tg2576 mice, modifier genes determining susceptibility to the lethal effects of the APP transgene have been mapped (16) . Similarly, in a YAC-based transgenic APP model, the level of APP processing was found to be dependent on the genetic background (17) . The TgCRND8 mouse model is an aggressive early onset model of brain amyloidosis (18) . These mice express, under the control of the hamster Prion protein promoter, the human APP gene harboring both the Swedish (K670N, M671L) and Indiana (V717F) familial AD mutations. This leads to elevated levels of Ab (especially Ab 42 ) within the brain. Diffuse and compact amyloid plaques associated with an inflammatory reaction appear as early as 10 weeks of age (19) , followed by progressive decline in cognitive function (18) . As seen in the other models of amyloid deposition, the genetic background of TgCRND8 mice also plays a role in determining the effects of transgene overexpression (18) . Our work describes the effects of the A/J genetic background on the Ab levels and plaque deposition in TgCRND8 mice. We observe differences not only in survival but also in the levels of amyloid deposition as compared to the mice on a B6 background. We performed a genome-wide linkage study to identify genes that modify the levels of Ab accumulation and deposition and report the identification of four QTLs on chromosomes 4, 11, 9 and 8, influencing to various extents the level of Ab peptides and their deposition into amyloid plaques in TgCRND8 animals.
RESULTS

Effect of genetic background in TgCRND8 mice
The survival of TgCRND8 mice is clearly affected by genetic background (18) . In our laboratory, the TgCRND8 mice were maintained on a mixed genetic background composed predominantly of FVB. To explore whether allelic variants issued from different inbred strains would alter the phenotype produced by the expression of the TgCRND8 transgene, we generated different strains of TgCRND8 mice by backcrossing to either B6 or A/J inbred mice. As can be seen in Figure 1A , mice that carry~75% A/J alleles in their genetic make-up show a much improved survival rate as compared to those (A) Kaplan-Meier survival plots for TgCRND8 mice with different genetic backgrounds: (solid line) A/J, n ¼ 76, or (dotted line) B6, n ¼ 55. Mice were monitored for survival once weaned at 3 weeks of age. (B and C) Groups of mice (n ¼ 3-4) were sacrificed at 8, 13 and 16 weeks of age and brains collected for immunohistochemical analysis with the Ab 1 -17 -specific antibody 6E10. Black bars represent TgCRND8 mice on a B6 genetic background and grey bars represent TgCRND8 mice with an A/J background. The data are expressed as the mean + SEM. In (B), the number of plaques that accumulate in the neocortical brain region normalized per mm 2 is depicted. In (C), the difference in amyloid burden is shown. The MannWhitney rank sum test or the Student's t-test was used to compare the number of plaques and amyloid burden measured in both backgrounds. Ã P , 0.05, ÃÃ P , 0.01, ÃÃÃ P , 0.001. (Fig. 1B) . This difference in amyloid deposition is further accentuated at 16 weeks of age (4.7 + 0.4 versus 6.7 + 0.3, P , 0.001). Similarly, the amyloid burden is significantly lower at both 13 and 16 weeks of age in TgCRND8 mice with A/J alleles (Fig. 1C) . As the level of human APP brain mRNA measured by real-time RT-PCR is comparable in both strains of mice from 8 to 16 weeks of age (unpublished data), we conclude that the A/J inbred mouse carries gene variants that decrease amyloid deposition in TgCRND8 mice.
Identification of modifiers of amyloid deposition in TgCRND8 mice
A genome scan approach was used to identify genes within the A/J inbred strain that contribute to decreasing the level of Ab accumulation and deposition in the brains of TgCRND8 mice. TgCRND8 mice carrying 75% A/J alleles were further backcrossed two times to the A/J strain to produce mice carrying a 94% A/J genetic background and are referred to as A.TgCRND8 mice. A.TgCRND8 were then crossed to B6 mice to generate F1 hybrids, which were subsequently intercrossed to produce (A.TgCRND8 Â B6)F2 progeny. Of the 400 mice generated, 201 that carried the human APP 695 (Swedish and Indiana) transgene were used in the QTL analysis. The mice were sacrificed at 21 weeks of age and their brains were collected for analysis. One hemisphere was analyzed by staining for amyloid deposition using both Thioflavin S (ThioS; compact plaques) and 6E10 (Ab-immunoreactive plaques). For each of these markers, the number of plaques and the amyloid burden were tabulated and served as quantitative traits for QTL mapping. To accommodate the genotyping platform, only 178 of the 201 (A.TgCRND8 Â B6)F2 intercross mice were genotyped with 80 microsatellite markers distributed at~20 cM intervals across the genome. Following this analysis, additional markers were added in areas containing QTLs for a total of 96 markers. Eventhough the mice were not explicitly examined for the presence of residual C3H alleles, the genotyping data revealed that C3H alleles have been retained by every single mouse at marker D7Mit83. This is consistent with the insertion of the transgene on the proximal part of chromosome 7 more specifically within a C3H chromosome. As the exact location of the putative insertion site and the size of the congenic interval have not been determined, our ability to detect modifier loci within this region of chromosome 7 is reduced. Analysis was performed with MapManagerQTXb19 (20) . The threshold levels for significance were determined empirically by running 10 000 permutations of the data and correspond to LOD scores of 1.4, 2.7 and 4.3 for suggestive, significant or highly significant linkage. As can be seen in Table 1 , the presence of four QTLs showing highly significant linkage to plaque number was revealed. The number of plaques found in the brains of 21-week-old F2 mice was most strongly linked to the D4Mit251 marker on chromosome 4 with a peak LOD score of 8.1 (P , 0.00001). This locus accounts for 19% of the phenotypic variance linked to the number of plaques. Three other QTLs, each accounting for 12 -13% of the variation, were found on chromosome 11 (D11Mit242, LOD score 5.5, P , 0.00001), chromosome 9 (D9Mit336, LOD score 5.0, P ¼ 0.00001) and chromosome 8 (D8Mit223, LOD score 4.5, P ¼ 0.00003). A/J alleles at these loci decreased the number of plaques in the brains of the (A.TgCRND8 Â B6)F2 progeny as compared to mice homozygous for the B6 alleles as can be seen in Figure 2 . If we examine the different alleles for these QTLs in pair wise combinations, it becomes evident that the effects of the QTLs are additive (Fig. 3) . For example, as demonstrated in Figure 3A , mice that are homozygous for the A/J alleles at D4Mit251 and D11Mit242 (n ¼ 12) have an average of 8.8 + 0.7 plaques as compared to 16.7 + 0.8 plaques in B6 homozygotes (n ¼ 15). About 55% of the variance in the number of plaques can be explained if the effects of the four QTLs are combined. This difference in the number of plaques is clearly seen when comparing mice with either A/J alleles or B6 alleles at these four proposed modifier genes. 
4B, D and F). Not surprisingly, these QTLs also control amyloid burden correlates with the actual number of plaques. Interestingly, the significance level for the four QTLs is somewhat modified as can be seen on the interval mapping curves in Figure 5 and the marker regression analysis in Table 1 . When looking specifically at amyloid burden, the most important QTL becomes the one on chromosome 9 with a peak LOD score Figure 6 demonstrates the allele effects for each of these QTLs on amyloid burden. Overall, the amyloid burden found in the brains of mice carrying A/J alleles at these modifier genes was clearly lower than in mice carrying B6 alleles. Although a fourth QTL on chromosome 8 was found to play a role in determining the number of plaques, it did not reach the level of high significance seen for the other QTL controlling amyoid burden in this panel of mice (Fig. 5D ).
QTL on chromosome 11 also controls soluble Ab 42 and soluble Ab 40 levels in the brain
The same panel of 201 (A.TgCRND8 Â B6)F2 mice was also phenotyped for Ab levels in the brain. For each mouse, the left hemisphere was homogenized, fractionated into soluble and insoluble fractions and analyzed for Ab 40 and Ab 42 content by ELISA. QTL analysis was performed for each of these phenotypes. Whereas no highly significant QTL was found to be linked to the levels of insoluble Ab 40 , the other phenotypes were partially controlled by a QTL on chromosome 11. As seen in Table 2 , the levels of both soluble Ab 40 and Ab 42 showed linkage with peak LOD scores of 4.9 and 7.2, respectively, at D11Mit242. The level of insoluble Ab 42 is also linked to this chromosomal region but the maximal LOD score is found at D11Mit213, which is~20 cM distal to D11Mit242, which may be indicative of a distinct QTL. As expected, A/J alleles at each of these QTL regions result in decreased levels of Ab. 2316
this does not exclude the possibility that other small-effect loci exist.
Plasma Ab levels are not controlled by the same modifiers identified for the brain amyloid phenotypes
In addition to the parameters that were examined in the brain, we were also interested in determining if these same modifier genes were also involved in controlling the levels of Ab found in the periphery. Plasma samples were isolated from our intercross progeny and sandwich ELISA used to quantify the level of Ab 40 and Ab 42 . The QTLs on chromosomes 4, 11, 9 and 8 were not detected. As can be seen in Table 3 , plasma Ab 42 was linked to markers on chromosome 6, whereas plasma Ab 40 was significantly linked to chromosomes 6 and 1.
DISCUSSION
It is widely accepted that genetic make-up plays a significant role in the development of AD. After age, genetic constitution is the most important risk factor in AD. As revealed by the number of studies published in recent years (14) , the hunt to identify genes involved in AD is intense. By far, the most useful tool in our understanding of AD has been the different mouse models created to reproduce particular features of the disease. This work shows that the genetic heterogeneity found in different inbred lines of mice can be used to modulate the progression of some features of AD pathology, a phenomenon reminiscent of what has been observed in humans. Thereby, these inbred lines of mice can be used to identify genetic modifiers that affect the development of AD 
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pathology. In this report, we demonstrate that the A/J genetic background imparts to the TgCRND8 mice a reduced propensity to accumulate and deposit Ab in the brain. Using a genome scan approach, we have identified loci on chromosomes 4, 11, 9 and 8 that modulate these phenotypes. Early on, it became evident that genetic background was important in determining the survival rate of TgCRND8 mice. Whereas TgCRND8 mice on FVB or 129SvEv/Tac backgrounds were quite susceptible to the overexpression of hAPP, the introduction of C3H genetic material resulted in an improved survival rate (18) . Interestingly, in other transgenic APP models, the 129S6 genetic background imparts resistance to APP overexpression (16) . In our colony, breeding TgCRND8 mice onto the A/J background generated mice that are completely resistant to the early lethal effects of APP overexpression, with survival rates approaching those of wild-type mice. These observations indicate that the A/J strain carries gene variants, which could provide resistance to the toxic effects of elevated Ab levels. Interestingly, over 95% of the (A.TgCRND8 Â B6)F2 intercross mice produced for our genome scan analysis survived to 21 weeks of age; it was therefore impossible to use age of death as a quantitative trait to map 'survival' genes from the A/J inbred strain. These findings are consistant with the presence of multiple susceptibility genes originating from the FVB or B6 strains necessary to induce premature death of TgCRND8 mice and are supported by recently published data in the Tg2576 model indicating that at least two genes exist on chromosomes 14 and 9 accounting for 25% of the variation in survival time (16) .
We have successfully identified highly significant QTLs on chromosomes 4, 11, 9 and 8 for which A/J alleles lead to a less severe amyloidogenic state. Interestingly, while the QTL on chromosome 11 is implicated in controlling both the accumulation of the various Ab peptides and their subsequent deposition into plaques, the QTLs on chromosomes 4, 8 and 9 show highly significant linkage only to the plaque deposition phenotypes (number of plaques and amyloid burden) but not Ab levels. These observations may be consistent with the QTL on chromosome 11 being specific to the development of AD, while the QTLs on chromosomes 4, 8 and 9 being involved in mechanisms underlying formation and deposition of amyloid, a process that may be relevant to all amyloid diseases. In other words, it is possible to speculate that the gene or genes underlying the chromosome 11 QTL may be involved in the production or clearance or transport of Ab peptides that are directly and specifically involved in the development of AD. In contrast, the other QTLs may have a greater impact on proteins such as proteoglycans or apolipoproteins or even metals, which are an integral part in the formation of various types of amyloid. In fact, this observation is supported by results of a recent report, as the QTL that was identified on chromosome 4 corresponds to the same genomic region where an A/J amyloidosis modifier has recently been mapped using a senile ApoAII amyloidosis model (21) . Alternatively, this inability to link the QTLs on chromosomes 4, 8 and 9 with the total levels of brain Ab40 and Ab42 peptides as measured by ELISA may reflect the fact that the homogenates used for the quantification comprised the entire brain hemisphere, whereas histological analysis of the amyloid plaques was carried out only on three sections of the brain. In other words, the level of Ab deposition is not uniform throughout the brain. In fact, marker regression analysis using plaque number for each brain section independently reveals that the levels of significance of the four QTLs vary. Finally, as can be seen in Figure 5 , whereas the QTLs on chromosomes 4 and 9 do not reach the threshold level for high significance, there is some indication that these may very well also control the levels of the different Ab peptides within the brain.
The QTL on chromosome 11 is significantly linked to all of the brain phenotypes examined except for the level of Figure 6 . QTLs on chromosomes 11, 4 and 9 affect amyloid burden. The (A.TgCRND8 Â B6)F2 mice were divided into groups corresponding to their genotypes at (A) D9Mit336, (B) D11Mit242 and (C) D4Mit251. AA represents mice that are homozygous for the A/J allele, AB represents mice that are heterozygous and BB represents mice that are homozygous for the B6 alleles. More specifically, the levels of insoluble Ab 42 found within the brain seem to be linked to the region distal to D11Mit242 and bordered by D11Mit213. Conversely, the levels of soluble Ab 40 , number of plaques and amyloid burden appear to be governed by the region between D11Mit236 and D11Mit36. Finally, the levels of soluble Ab 42 are significantly linked to the entire interval. This large genomic interval contains~840 genes. A survey of the publicly available databases reveals a few known genes with coding region SNPs resulting in amino acid differences between A/J and B6 genomes: serine carboxypeptidase 1 (Scpep1), ATP-binding cassette, subfamily C (CFTR/MRP), member 3 (Abcc3), ring finger protein 130 (Rnf130) or cold autoinflammatory syndrome 1 homolog (Cias1). Further studies will be required to determine the role of these genes in modulating the extent of Ab accumulation. The QTLs on chromosomes 4, 8 and 9 are all involved in the process of plaque deposition possibly determining the actual number of plaques or controlling the size of the plaques that develop. By comparing the level of significance of each loci for either phenotype, the QTL on chromosome 4 appears to contribute more to the mechanisms underlying initial formation or seeding of the plaque, whereas the QTL on chromosome 9 may contribute more to the control of plaque growth following the initial seeding. In contrast, the QTL on chromosome 8 displays comparable levels of significance with respect to the number of plaques and amyloid burden and may be central to both mechanisms.
The region covered by the QTL on chromosome 4 is 24 Mb long and includes~350 genes. It is homologous to human chromosome 1p, which has been linked to AD in human populations (22 -24) . As stated above, this chromosomal segment has been previously described as modifying the formation of amyloid in an ApoAII model of amyloidosis (21) and perlecan (Hspg2) is proposed as a candidate gene within this region. Perlecan is a basement membrane proteoglycan that codeposits with amyloid and as such remains an interesting candidate (25) . The QTL on chromosome 9 is quite large covering over 50 Mb, making it quite difficult to propose candidate genes within the interval. The proximal part of this interval was recently implicated by genome-wide analysis in susceptibility to the lethal effects of APP trangene overexpression in the Tg2576 human APP mouse (16) . The QTL on chromosome 8 encompasses a rather small genomic region of 9 Mb and includes 67 genes. The syntenic region in the human genome has not yet been linked to AD. Interestingly, Phinney et al. (26) have described a mutation within the ATPase7b transporter, which is located in the proximal part of chromosome 8 that when crossed to the TgCRND8 mouse results in the deposition of fewer amyloid plaques. Further analysis of the A/J and B6 alleles of this transporter may reveal functional differences. Of note, is the presence of a coding region SNP in the A/J and B6 alleles of the Wrn gene that results in an amino acid substitution. This gene codes for a protein that is mutated in Werner syndrome, a disease that is characterized by premature aging (27) .
In light of recent evidence describing the importance of vascular Ab as a seed in the formation of amyloid plaques, it will be interesting to determine whether the QTLs described here also influence vascular deposition of Ab in this model. Characterization of candidate genes in these QTL regions may allow for the identification of novel genes involved in amyloid production and deposition. Such genes may help to explain the mechanisms at play in the development of AD in humans. More importantly, these genes or genomic regions can be a part of pharmacogenomic screens that will help to differentiate AD patients with regards to the course of their disease and perhaps the response to potential therapies that will be available in the not-so-distant future.
MATERIALS AND METHODS
Mice
The TgCRND8 [official designation B6C3-Tg(APP SwInd ) 8Dwst] model expresses a double mutant of the human APP 695 gene (Swedish K 670 M 671 !NL and Indiana V 717 !F) driven from a hamster Prion promoter (18) . These mice were originally produced by microinjection of (C3H Â B6) Â B6 oocytes. The founder was maintained by first backcrossing for two generations to C3H mice and subsequently to FVB for three additional generations. The incipient congenic strain used to generate the panel of mice for QTL mapping was produced by backcrossing for four generations to the A/J strain and is refered to as A.TgCRND8. The genetic background of the A.TgCRND8 mice is composed of 94% A/J, 5.5% FVB and 0.5% C3H. All mice were maintained in an animal facility under the conditions specified by the Canadian Council on Animal Care.
TgCRND8 genotyping
TgCRND8 mice are maintained in a hemizygous state and need to be genotyped for the presence or absence of transgene after each generation of breeding. Hair follicles are collected at weaning, incubated for 7 min at 988C in 50 mM NaOH and then rapidly cooled on ice. After neutralization with 1 M Tris (pH 7), 2 -3 ml are used in a PCR reaction with primers (5 0 -GTCTACCCTGAACTGCAGATCA-3 0 ; 5 0 -TTGCACCA GTTCTGGATGGT-3 0 ) that amplify both the transgenic human APP and the wild-type mouse App alleles. Due to a difference of four nucleotides in the amplicon between the human APP allele and the endogenous mouse App allele, the melting temperature of the amplicon can be used to discriminate transgenic (80.38C) from non-transgenic mice (81.78C).
Human APP mRNA expression 
Brain preparation
Mice were transcardially perfused with saline solution. Brains were dissected out and separated in hemispheres. The right hemisphere was snap-frozen and kept at 2808C for Ab level determination. The left hemisphere was immersed in freshly prepared 4% paraformaldehyde for 3 h at 48C, and then transferred into 30% sucrose at 48C. When cryoprotection was achieved (16 -48 h), brains were frozen in isopentane at 2458C and subsequently stored at 2808C for histological studies.
Histochemical staining
Forty-micron thick sections were prepared. For ThioS staining, brain sections were mounted on Super Frost slides and allowed to dry before staining with 1% ThioS in water. After differentiation of the ThioS staining, sections were counterstained with hematoxylin for 5 min. For immunohistochemistry, free-floating sections were washed and pretreated to block endogenous peroxidase. Ab immunoreactivity was detected using a 1:1000 dilution of 6E10-biotinylated (Senetek, MA, USA) incubated overnight at 48C. After amplification with avidin -biotin complex kit (Vector Laboratories, ON, Canada), the reaction was developed by Ni-3,3 0 -diaminobenzidine/H 2 O. Three brain sections, taken at levels 22.1, 22.8 and 23.4 mm from the bregma, were analyzed for each mouse (28) . A quantitative image analysis of plaque deposition was performed using Image Pro Plus software (Media Cybernetics, MD, USA) for 6E10 and ThioS. Parameters measured include the number of plaques as well as the amyloid burden. The amyloid burden is defined as the percentage of the neocortical area analyzed that is occupied by Thio-S or 6E10-positive plaques.
Quantification of human Ab 40 and Ab 42 levels
Perfused brains were homogenized in four volumes of ice-cold 50 mM Tris -HCL pH 8.0 containing protease inhibitors. The homogenates were vortexed and centrifuged at 16 000g for 20 min at 48C. Supernatants were further treated with 8 M and 5 M guanidine-HCL/50 mM Tris -HCL pH 8.0 (1 volume supernatant: 1.7 volumes 8 M guanidine -HCL/ 50 mM Tris -HCL pH 8.0: 2.7 volumes 5 M guanidine -HCL/50 mM Tris -HCL pH 8.0) and pellets were treated with 7 volumes 5 M guanidine-HCL/50 mM Tris -HCL pH 8.0. Supernatants were identified as soluble fractions and pellets were identified as insoluble fractions. Both soluble and insoluble fractions were frozen, thawed at room temperature, sonicated 15 min at 808C, cooled at room temperature and frozen on dry ice for 10 min. Fractions were then thawed again, sonicated 10 min at 808C and cooled at room temperature. The soluble and insoluble fractions were centrifuged at 16 000g for 20 min at 48C. Supernatants of both fractions were stored at -808C until Ab quantification. Fractions were thawed and sonicated 5 min at 808C just before quantification of Ab. The quantification was performed in duplicate using fluorometric ELISA kits specific for Ab 40 or Ab 42 (BioSource International Inc., Camarillo, CA, USA). Procedures were followed as recommended by the manufacturer. Quantification of the plasma samples was done without any sample preparation.
QTL mapping
A.TgCRND8 and C57BL/6 inbred mice were used to produce 201 F2 progeny. Genomic DNA was extracted from the tails of the F2 progeny. Briefly, a 0.5 cm piece of tail was incubated in lysis buffer (10 mM Tris, 100 mM EDTA, 0.6% SDS, 400 mM NaCl, 0.75 mg/ml proteinase K) at 558C for 16 h. DNA was precipitated in ethanol and resuspended in water. Some 10 mg/ml dilutions in water were prepared and sent to the McGill University and Genome Quebec Innovation Center for genotyping. A panel of 96 microsatellite markers spaced at~20 cM intervals was used in this study. Markers were chosen based on their ability to differentiate between B6 and A/J alleles. Of these markers, 55 were also able to differentiate the FVB alleles. To allow the analysis of the data by MapManagerQTX, the mice that carried one FVB allele were scored as heterozygotes (carrying at least one B6 or A/J allele). Whereas no residual FVB alleles were detected at markers D4Mit251 and D8Mi223, the presence of FVB alleles at D9Mit336 and D11Mit242 was seen, but this did not affect the detection of the respective QTLs. The presence of C3H alleles was not considered in the selection of markers as they theoretically comprise less than 0.4% of the genetic make-up of the F2 mice. The complete list of markers used in the analysis is available upon request. All mice were sacrificed at 21 weeks of age. Plasma was collected from each mouse by transcardial puncture for the determination of Ab levels. The brain was isolated following perfusion with isotonic saline solution. Histochemical staining of the left brain hemisphere allowed us to quantify the plaque number and also amyloid burden. The right hemisphere was used to determine Ab levels. For each of these phenotypes, marker regression analysis and interval mapping was performed using MapManager QTXb19 (20) . The levels of significance were determined empirically for each individual phenotype by performing 10 000 permutations of the data. The LOD scores corresponding to suggestive (1.4), significant (2.7) and highly significant (4.3) linkage were found to be very similar between phenotypes.
Box-plot graphs
Box plot limit closest to 0 represents the 25th percentile; the limit farthest from 0 represents the 75th percentile. Whiskers above and below the boxes indicate the 90th and 10th percentiles, respectively. Median values are represented by bars within the boxes. 
